Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
45 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Consecutive participants with breast cancer or lymphoma scheduled to receive anthracycline-based chemotherapy or trastuzumab.
Stage I-III breast cancer or lymphoma with a >2 year life expectancy
A treatment plan that includes anthracyclines and/or trastuzumab
Age >45 years
Able to hold breath for 10 seconds
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Refusal or inability to provide informed consent
Known heart failure or LVEF <50%
Heart rate over 100 bpm
Renal dysfunction with GFR <30 mL/min/1.73m2
Participants with pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices